Cardiovascular risk assessment in patients with chronic and recurrent pancreatitis-preliminary data

Abstract

s / Pancreatology 16 (2016) S1eS130 S16 Patients & methods: 58 patients with advanced pancreatic adenocarcinomawere selected in three institutions. chemo-responsiveness of all patients was assessed with ct before and after receiving at least 3 cycles of gemcitabine-based chemotherapy. hounsefield unit (HU) was measured in pancreatic mass and the largest metastatic liver mass using region of interest. HU difference between arterial and pre-contrast phase (Delta value) could reflect vascular enhancement. According to chemo-responsiveness, the patients were divided into 2 group, Responder group (partial response and stable disease) and non-responder group (Progressive disease). Results: A total of 58 patients were included in the study. 41 patients belonged to pancreatic responder group (70.7%) and 17 patients belonged to pancreas non-responder group (29.3%). Mean delta value in pancreas responder group and non-responder group was 48.9 and 24.6 (p < 0.001). 29 of 59 patients had liver metastasis. 19 of 29 patients belonged to liver responder group and 10 patients belonged to liver non-responder group. mean delta value in liver responder group and non-responder group was 36.68 and 12.30 (p1⁄40.031). four patients showed inconsistency between pancreas and liver chemo-responsiveness. They all belonged to pancreas responder group (median delta value 35; range 30-44) and liver nonresponder group (13;range 6-16) Conclusion: Vascular enhancement pattern of the mass in ct may predict chemo-response in pancreatic cancer with liver metastasis.